BACKGROUND Antithrombotic therapy for acute myocardial infarction (MI) with atrial fibrillation (AF) among higher
Current guidelines for the management of AF recommend anticoagulation for thromboembolic prophylaxis in AF patients who are at average or higher risk for stroke but not at prohibitive risk for bleeding (1) . Guidelines for the management of acute MI and PCI patients recommend treatment with dual antiplatelet therapy (DAPT) to reduce the risks of major adverse cardiac events (MACE) and stent thrombosis (2) ; however, clinicians may be reluctant to treat AF patients with concurrent indications for DAPT by using the combination of warfarin, aspirin, and clopidogrel (triple therapy) due to the high bleeding risk associated with this regimen (3, 4) .
Although previous studies have found that bleeding risk is higher among patients receiving triple therapy (4) (5) (6) , some data also suggest a lower risk of MACE among patients treated with triple therapy relative to DAPT (7, 8) . Given the paucity of randomized data, studies have shown variability in anticoagulant agent use according to the predicted risks of stroke and bleeding in this patient population (8) (9) (10) (11) .
Therapeutic decisions for older patients with AF and coronary artery disease may be especially challenging. Older patients in particular are at greater risk for AF-related stroke and recurrent events after acute MI but also have a higher risk for bleeding events (12) . 
METHODS
DATA SOURCES. Clinical and procedural data for our study were obtained from the ACTION Registry-GWTG, a national quality improvement registry capturing data on consecutive MI patients treated at >500 hospitals in the United States; this registry has been described previously (13) . Because patient information was collected without unique patient identifiers, we used indirect identifiers in combination (date of birth, sex, hospital identification, date of admission, and date of discharge) to link patients $65 years of age in the ACTION Registry-GWTG with Medicare claims data (methods previously described) (14) . The linked data for our analysis were available Registry-GWTG data collection form. We excluded patients who died during the index hospitalization (n ¼ 374), were transferred out to another acute care hospital (n ¼ 63), and who left against medical advice or were discharged on comfort measures or to hospice (n ¼ 74). Also excluded were patients who were not discharged on both aspirin and a P2Y 12 antagonist (clopidogrel, prasugrel, or ticlopidine; n ¼ 444), patients with a documented contraindication to warfarin (n ¼ 103), patients with missing data on discharge warfarin use (n ¼ 16), and nonindex admissions for patients with multiple records (n ¼ 65).
Our final analysis population consisted of 4,959 patients treated at 400 sites. A breakdown of the data source used to identify AF patients is shown in the Online Appendix.
OUTCOMES AND DEFINITIONS. The primary effectiveness outcome for our study was MACE at 2 years, defined as death or readmission for MI or stroke (ischemic and hemorrhagic). Secondary effectiveness outcomes included individual components of the composite MACE outcome, as well as ischemic stroke alone. We also examined bleeding readmission within 2 years after the index hospitalization as our primary safety endpoint, as well as readmissions involving intracranial hemorrhage. Outcomes were identified by using International Classification of DiseasesNinth Revision codes (Online Appendix) from Medicare inpatient claims data.
Patients were classified according to stroke risk by using the CHADS 2 (congestive heart failure, hypertension, age $75 years, diabetes, prior stroke or transient ischemic attack) risk score (15 Atrial Fibrillation) risk score (16) . ATRIA scores were summed by assigning 3 points each for anemia (hemoglobin <13 g/dl in men, <12 g/dl in women) or severe renal disease (glomerular filtration rate <30 ml/ min or dialysis dependent), 2 points for age $75 years, and 1 point each for hypertension or prior bleeding.
An ATRIA score >3 was considered high bleeding risk.
As a sensitivity analysis, post-discharge warfarin and P2Y 12 inhibitor prescription fill information was obtained from a Medicare Part D prescription claims database (n ¼ 1,591). We then examined medication persistence at 90 days after discharge from the index MI hospitalization, defined as continuation of the medication prescribed at discharge without a gap in filling >60 days (17) . We also examined warfarin initiation post-discharge by determining time to first warfarin prescription fill post-discharge.
STATISTICAL ANALYSIS. Baseline clinical and procedural characteristics were described according to discharge on DAPT versus triple therapy. Continuous and categorical variables were presented by using medians with interquartile ranges and proportions, respectively, and compared by using respective Wilcoxon rank-sum and chi-square tests. Kaplan-Meier estimates of all-cause mortality and MACE outcomes were reported, and readmission outcomes were reported by using the cumulative incidence function to account for the competing risk of death. Follow-up for all outcomes was started at the time of discharge from the index hospitalization. Inverse probability weighting was used to account for confounding by observed covariates, and the relationship between discharge therapy and outcomes was assessed as intention-to-treat. Propensity scores were estimated by using logistic regression with triple therapy versus DAPT as the outcome to determine the probability of each patient undergoing the treatment he or she received conditional on observed covariates. The inverse of this probability was then assigned as each patient's "weight." Unadjusted and adjusted Cox proportional hazard models were fit for each outcome of interest: unadjusted models included discharge therapy as the sole variable, and weights were then applied in adjusted models. The proportional hazards assumption was met for all models, and covariates were adequately balanced after propensity score weighting (Online Appendix). Hazard ratios (HRs) for triple therapy versus DAPT and corresponding 95% confidence intervals (CIs) were reported.
The following variables were used in the propensity models (these covariates were selected on the Hess et al. Hess et al.
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Triple Therapy Use in MI and AF No. at risk Cumulative incidence curves for triple therapy versus DAPT for: (A) bleeding readmission and (B) intracranial hemorrhage. Abbreviation as in Figure 1 .
Triple Therapy Use in MI and AF discharged on warfarin were started on warfarin in the next 3 months. Some of these delayed initiations may be due to completion of the P2Y 12 inhibitor treatment course, resolution of in-hospital bleeding events, recurrence of AF events, or perhaps deferral of treatment decisions to an outpatient care provider.
Further investigation may help to clarify the benefits and risk of upfront versus delayed anticoagulation in these PCI-treated patients with AF.
Our study suggests that, compared with DAPT, triple therapy use is not associated with lower MACE risk among older acute MI patients with a history of AF undergoing coronary stenting. The 90-day landmark analysis confirms these findings among patients who remain on warfarin therapy for at least 90 days versus those who were not anticoagulated. Furthermore, we tested for interactions among multiple subgroups and found no evidence of any association of triple therapy with outcomes. There was, however, a nonsignificant trend for lower risk of ischemic stroke associated with triple therapy, an endpoint for which warfarin might be expected to have the greatest potential benefit. These findings differ from a previous report of increased mortality among hess@duke.edu.
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